Bruker Daltonics Introduces RAID-XP, a Novel Hand-held Homeland Security Instrument that Combines Nuclear and Chemical Agent Detection.Business Editors/Health/Medical Writers/High-Tech Writers GOTHENBURG, Sweden--(BUSINESS WIRE)--June 2, 2004 Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces the RAID(TM)-XP, a combined portable instrument to detect chemical and radiation threats. The rapidly increasing demands on defense and homeland security have led to the urgent need for reliable radiation and chemical agent detection in a single, lightweight instrument. Based on the outstanding chemical detection capability with low false positive alarm rates of its well-proven RAID-M ion mobility spectrometer An ion mobility spectrometer (IMS) is a spectrometer capable of detecting and identifying very low concentrations of chemicals based upon the differential migration of gas phase ions through a homogeneous electric field. , and the superior gamma detection capability of its SVG-2 radiation meter, Bruker Daltonics introduces the new RAID-XP today at the 8th International Symposium on Protection against Chemical and Biological Warfare Agents in Gothenburg. The combination of two detection technologies within one easy-to-use, portable instrument allows a versatile response to a wide range of threats. Its chemical detection capabilities include the classical chemical warfare agents (CWAs), as well as threats arising from toxic industrial chemicals (TICs). The RAID-XP radiological detection capability includes gamma radiation dose rate detection and integrated total accumulated dose calculation. Frank Laukien, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented: "The new RAID-XP clearly can enhance the capabilities of our defense and homeland security forces to respond to potential WMD WMD white muscle disease. threats. We believe this unique dual-purpose system will be well received by potential users." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion